{
    "title": "Regeneron cuts top end of eye drug sales forecast",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-2820275/Regeneron-cuts-end-eye-drug-sales-forecast.html",
    "date": "2014-11-04",
    "keywords": [
        "drug",
        "eylea",
        "end",
        "dme",
        "forecast",
        "percent",
        "regeneron",
        "eye",
        "adoption",
        "company",
        "wet",
        "inc",
        "gmt",
        "november",
        "email",
        "grovernov",
        "blockbuster",
        "type",
        "swelling",
        "fastestgrowing",
        "history",
        "biotechnology",
        "degeneration",
        "cause",
        "blindness",
        "narrowing",
        "signal",
        "range",
        "uptake",
        "edema",
        "approval",
        "july",
        "case",
        "amdunlike",
        "amd",
        "treatment",
        "performance",
        "product",
        "year",
        "officer",
        "robert",
        "call",
        "bit",
        "urgency",
        "date",
        "condition",
        "threat",
        "vision",
        "capital",
        "analyst",
        "butt",
        "headtohead",
        "study",
        "institutes",
        "health",
        "growth",
        "driver",
        "quarter",
        "bayer",
        "agregeneron",
        "sa",
        "cholesterollowering",
        "trial",
        "risk",
        "heart",
        "strokesregeneron",
        "sanofi",
        "race",
        "amgen",
        "class",
        "medicine",
        "voucher",
        "sixmonth",
        "review",
        "companys",
        "stock",
        "midday",
        "tuesday",
        "nasdaq",
        "editing",
        "dsouza",
        "paxton"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}